BioMendics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $7M
Latest Deal Amount
  • Investors
  • 4

BioMendics General Information

Description

Developer of wound-healing products designed to treat and cure wounds. The company's wound-healing products blends liquid crystalline biomimetics with natural products to produce a cutting-edge accelerated healing products for the treatment of chronic wounds, enabling patients to get relief from the wounds.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 118 East Rosewood Avenue
  • 4209 Street Right 44 Post Office Box 95
  • Rootstown, OH 44272
  • United States
+1 (330) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioMendics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 06-Sep-2016 $7M 00.000 Completed Startup
3. Accelerator/Incubator 28-Jun-2016 00000 00000 Completed Startup
2. Accelerator/Incubator 10-Dec-2014 $25K Completed Startup
1. Accelerator/Incubator Completed Startup
To view BioMendics’s complete valuation and funding history, request access »

BioMendics Patents

BioMendics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018306420-A1 Substituted tolans for the modulation of microbial colonization Pending 27-Jul-2017 000000000
CA-3070427-A1 Substituted tolans for the modulation of microbial colonization Pending 27-Jul-2017 000000000
EP-3658128-A4 Substituted tolans for the modulation of microbial colonization Pending 27-Jul-2017 000000000 0
JP-2020529471-A Substitution tran to suppress microbial colony formation Pending 27-Jul-2017 000000000
EP-3658128-A1 Substituted tolans for the modulation of microbial colonization Pending 27-Jul-2017 A61P31/00

BioMendics Executive Team (1)

Name Title Board Seat Contact Info
Karen McGuire Ph.D Chief Executive Officer & Founder
To view BioMendics’s complete executive team members history, request access »

BioMendics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JumpStart Venture Capital Minority 000 0000 000000 0
Great Lakes Innovation and Development Enterprise Accelerator/Incubator 000 0000 000000 0
Innovation Fund of Northeast Ohio Accelerator/Incubator 000 0000 000000 0
REDIzone Accelerator/Incubator 000 0000 000000 0
To view BioMendics’s complete investors history, request access »